Director Mark C. McKenna purchases 20,000 shares of APGE across 2 transactions for $990,775.00 total, establishing new 20.0K share position.
Director Mark C. McKenna acquired 20,000 shares through 2 separate purchases on 2024-12-12, at blended average price of $49.54, totaling $990,775.00. This represents his first documented shareholding position in Apogee Therapeutics. The company is currently trading at $47.21, down 32.4% from its 52-week high of $69.80, and posted negative net income of $-49,018,000.00 in its most recent full fiscal year. The transaction reflects a director's direct equity investment into an unprofitable biotech company trading well below recent highs, though the absence of prior holdings and trade history at this ticker limits inference about conviction levels or strategic positioning relative to his own historical patterns.